目的 探討舒腦欣滴丸聯(lián)合鹽酸洛美利嗪膠囊治療偏頭痛的臨床療效。方法 選擇2019年2月—2019年6月在天津市北辰醫(yī)院治療的偏頭痛患者88例，根據(jù)用藥的差別分為對(duì)照組（44例）和治療組（44例）。對(duì)照組口服鹽酸洛美利嗪膠囊，5 mg/次，2次/d；治療組在對(duì)照組基礎(chǔ)上口服舒腦欣滴丸，4粒/次，3次/d。兩組患者均經(jīng)過(guò)4周治療。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者癥候評(píng)分，PSQI、SF-36和VAS評(píng)分，血清環(huán)氧化酶-2（COX-2）、溶血磷脂酸（LPA）、神經(jīng)元特異性烯醇酶（S-NSE）、同型半胱氨酸（Hcy）、血栓烷素2（TXB2）和5-羥色胺（5-HT）水平。結(jié)果 治療后，對(duì)照組臨床有效率為81.82%，顯著低于治療組的97.73%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。經(jīng)治療，兩組患者癥候評(píng)分、PSQI和VAS評(píng)分均明顯下降（P<0.05），而SF-36評(píng)分明顯升高（P<0.05），且治療組這些評(píng)分明顯好于對(duì)照組（P<0.05）。經(jīng)治療，兩組患者血清COX-2、LPA、S-NSE、Hcy、TXB2水平均明顯降低（P<0.05），而5-HT水平均明顯升高（P<0.05），且治療組患者血清學(xué)指標(biāo)水平明顯好于對(duì)照組（P<0.05）。結(jié)論 舒腦欣滴丸聯(lián)合鹽酸洛美利嗪膠囊治療偏頭痛可有效改善患者臨床癥狀，提高患者睡眠及生活質(zhì)量，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical efficacy of Shunaoxin Dropping Pills combined with lomerizine in treatment of Migraine. Methods Patients (88 cases) with migraine in Tianjin Beichen Hospital from February 2019 to June 2019 were divided into control (44 cases) and treatment (44 cases) groups based on different treatments. Patients in the control group were po administered with Lomerizine Hydrochloride Capsules, 5 mg/time, twice daily. Patients in the treatment group were po administered with Shunaoxin Dropping Pills on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the scores of symptom, PSQI, SF-36 and VAS, the serum levels of COX-2, LPA, S-NSE, Hcy, TXB2 and 5-HT in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.82%, which was significantly lower than 97.73% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the scores of symptom, PSQI and VAS in two groups were significantly decreased (P<0.05), but the SF-36 scores were significantly increased (P<0.05), and these scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the serum levels of COX-2, LPA, S-NSE, Hcy and TXB2 in two groups were significantly decreased (P<0.05), but the 5-HT levels were significantly increased (P<0.05), and these serological indexes in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Shunaoxin Dropping Pills combined with lomerizine in treatment of migraine can effectively improve the clinical symptoms of migraine patients, and improve the sleep and quality of life of patients, which has a certain clinical application value.

R971